Treatment of tumour bearing mice with liponsome-entrapped actinomycin D prolongs their survival.
The possibility of employing liposome-entrapped actinomycin D for the treatment of AKR mice inoculated with AKR-A cells was examined. It was found that injection of actinomycin D after its entrapment in liposomes prolonged the survival of such mice to a greater extent than did similar amounts of free actinomycin D. Data from in vitro experiments suggest that entrapped actinomycin D could localize in the nucleus of AKR-A cells presumably following endocytosis of the liposomal carrier and subsequent liberation of the drug in, and its diffusion from, the lysosomes.
D000818:Animals; D001345:Autoradiography; D003609:Dactinomycin / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D008081:Liposomes / Q000378:metabolism / Q000627:therapeutic use*; D008223:Lymphoma / Q000188:drug therapy*; D051379:Mice; D008806:Mice, Inbred AKR; D008938:Mitosis / Q000187:drug effects; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D013210:Staphylococcus / Q000187:drug effects; D013997:Time Factors
D008081:Liposomes; D003609:Dactinomycin